Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial

Зохиогч

Batmunkh, Tsetsegsaikhan

Moore, Kerryn A.

Thomson, Helen

Altangerel, Bolor

Amraa, Otgonjargal

Avaa, Naranbaatar

Batbayar, Lkhagvagaram

Batsukh, Khishigjargal

Bright, Kathryn

Burentogtokh, Tsogjargal

Ha Do, Lien Anh

Hart, John D.

Javkhlantugs, Khulan

Jigjidsuren, Sarantsetseg

Justice, Frances

Li, Shuo

Licciardi, Paul V.

Mashbaatar, Khaliunaa

Mazarakis, Nadia

Neal, Eleanor F.G.

Nguyen, Cattram Duong

Ochirbat, Batbayar

Tuya, Alimaa

Surenjav, Unursaikhan

von Mollendorf, Claire

Mulholland, Kim

Он

2024 оны нэгдүгээр сар

Төрөл

journal article

Хэвлэгч

Elsevier BV

Journal

The Lancet Regional Health - Western Pacific

Volume

42

Start Page

100953

DOI

ISSN

2666-6065